Arena/Pfizer Deal History & Licensing Activity
Arena/Pfizer is a large pharma headquartered in US. Over the past three years, Arena/Pfizer has been involved in 14 licensing and acquisition transactions, with a primary focus on Small Molecules (10 deals). The company currently has 50 active clinical trials, primarily in Metabolic.
Deals (12mo)
8
Active Trials
50
Top Modality
Small Molecules
Focus Area
Metabolic
Arena/Pfizer Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Arena/Pfizer in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| YP05002 | Pfizer Inc. | Small Molecules | Phase 1 | collaboration | Dec 9, 2025 |
| YP05002 | Pfizer | Small Molecules | Phase 1 | license | Dec 9, 2025 |
| YP05002 | Pfizer | Small Molecules | Phase 1 | collaboration | Dec 9, 2025 |
| Metsera obesity portfolio (MET-097i, MET-233i) | Pfizer | Small Molecules | Preclinical | acquisition | Sep 22, 2025 |
| berobenatide (PF-08653944) | Pfizer | Peptides | Unknown | acquisition | Sep 22, 2025 |
| MET-097i / MET-233i | Pfizer | Peptides | Phase 1 | acquisition | Sep 22, 2025 |
| Undisclosed | Pfizer | Other | Unknown | acquisition | Sep 22, 2025 |
| MET-097i + MET-233i | Pfizer | Small Molecules | Phase 2 | acquisition | Sep 22, 2025 |
Arena/Pfizer Pipeline Focus
Therapeutic areas and modalities where Arena/Pfizer is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Arena/Pfizer Clinical Pipeline
Arena/Pfizer has 50 active clinical trials across 6 development phases.
8
Unknown
3
Phase 4
1
Not Applicable
14
Phase 1
9
Phase 2
15
Phase 3
See How Your Asset Matches Arena/Pfizer's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Metabolic assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Arena/Pfizer Licensing & Deal Activity
Arena/Pfizer is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 14 deals over the past three years, Arena/Pfizer ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Arena/Pfizer include Metabolic (21 deals and trials), Solid Tumors (12 deals and trials), Infectious (7 deals and trials), and Autoimmune (6 deals and trials). In terms of modality, Arena/Pfizer has shown particular interest in small molecules, peptides, bispecific antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Arena/Pfizer and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Arena/Pfizer's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.